Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP4F2 | P78329 | 1/20 | 0.59 |
| ▸ | CYP4A11 | Q02928 | 1/20 | 0.59 |
| ▸ | LTA4H | P09960 | 6/20 | 0.54 |
| ▸ | LMNA | P02545 | 1/20 | 0.52 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.52 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.49 |
| ▸ | PPARG | P37231 | 1/20 | 0.48 |
| ▸ | PPARD | Q03181 | 1/20 | 0.48 |
| ▸ | PPARA | Q07869 | 1/20 | 0.48 |
| ▸ | CYP4Z1 | Q86W10 | 1/20 | 0.48 |
| ▸ | FFAR1 | O14842 | 1/20 | 0.48 |
| ▸ | CYSLTR2 | Q9NS75 | 1/20 | 0.47 |
| ▸ | CYSLTR1 | Q9Y271 | 1/20 | 0.47 |
| ▸ | MAPT | P10636 | 1/20 | 0.47 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL28538108 | 0.87 | CYP4F2 (0.60) | CYP4F2CYP4A11LTA4HLMNAL3MBTL1 | |
| SCHEMBL7279461 | 0.86 | CYP4F2 (0.59) | CYP4F2CYP4A11LTA4HLMNAL3MBTL1 | |
| SCHEMBL2444683 | 0.86 | CYP4F2 (0.55) | CYP4F2CYP4A11LTA4HLMNAL3MBTL1 | |
| SCHEMBL30257467 | 0.85 | LTA4H (0.56) | LTA4HCYSLTR2CYSLTR1MAPT | |
| SCHEMBL7037985 | 0.85 | ADRB2 (0.53) | LTA4HLMNAL3MBTL1PPARGFFAR1 | |
| SCHEMBL3581393 | 0.85 | TBXAS1 (0.56) | LTA4HPPARG | |
| SCHEMBL1745109 | 0.84 | FFAR1 (0.69) | CYP4F2CYP4A11LTA4HLMNAL3MBTL1 | |
| SCHEMBL8000090 | 0.84 | LTA4H (0.57) | CYP4F2CYP4A11LTA4HLMNAL3MBTL1 | |
| SCHEMBL11566476 | 0.83 | CYP4F2 (0.56) | CYP4F2CYP4A11LTA4HLMNAL3MBTL1 | |
| SCHEMBL11564286 | 0.83 | CYP4F2 (0.56) | CYP4F2CYP4A11LTA4HLMNAL3MBTL1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1559422-B1 | RECEPTOR FUNCTION CONTROLLING AGENT | TAKEDA PHARMACEUTICAL (JP) | 2014-04-30 | — | — | EP | disclosed |
| EP-2385032-A1 | GPR40 Receptor function regulator | Takeda Pharmaceutical Company Limited (JP) | 2011-11-09 | — | — | EP | disclosed |
| US-7960369-B2 | Receptor function regulator | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2011-06-14 | — | — | US | disclosed |
| US-20090012093-A1 | Receptor Function Regulator | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2009-01-08 | — | — | US | disclosed |
| EP-1559422-A1 | RECEPTOR FUNCTION CONTROLLING AGENT | Takeda Pharmaceutical Company Limited (JP) | 2005-08-03 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090012093-A1 | Receptor Function Regulator | GPR119, GIPR, INSR | CYP4F2 2792/4885CYP4A11 2007/4885LTA4H 1978/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.